about
Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccineThe Sin3a repressor complex is a master regulator of STAT transcriptional activityVaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infectionScavenger receptor BI and BII expression levels modulate hepatitis C virus infectivityNeutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic ReviewImpact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationComparison of qualitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus (HCV) RNA detection and quantification: impact on diagnosis and treatCell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitroCell Culture Adaptation of Hepatitis C Virus and In Vivo Viability of an Adapted VariantRole of the Hepatitis C Virus Core+1 Open Reading Frame and Core cis-Acting RNA Elements in Viral RNA Translation and ReplicationProduction of Infectious Genotype 1b Virus Particles in Cell Culture and Impairment by Replication Enhancing MutationsDiscovery of (7R)-14-cyclohexyl-7-{[2-(dimethylamino)ethyl](methyl) amino}-7,8-dihydro-6H-indolo[1,2-e][1,5]benzoxazocine-11-carboxylic acid (MK-3281), a potent and orally bioavailable finger-loop inhibitor of the hepatitis C virus NS5B polymeraseVaccine developmentAntigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for childrenCurrent status and progress of prepandemic and pandemic influenza vaccine development.Prepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.Head-to-head comparison of pandemic influenza vaccines.Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.A randomised, single-blind, dose-range study to assess the immunogenicity and safety of a cell-culture-derived A/H1N1 influenza vaccine in adult and elderly populations.Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice.A dose-ranging study in older adults to compare the safety and immunogenicity profiles of MF59®-adjuvanted and non-adjuvanted seasonal influenza vaccines following intradermal and intramuscular administration.Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses.Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness.Persistence of antibodies 20 y after vaccination with a combined hepatitis A and B vaccine.Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum.Genetic Adaptation and Neandertal Admixture Shaped the Immune System of Human PopulationsLipoprotein lipase inhibits hepatitis C virus (HCV) infection by blocking virus cell entryViral entry and escape from antibody-mediated neutralization influence hepatitis C virus reinfection in liver transplantationUnmet needs in modern vaccinology: adjuvants to improve the immune response.Challenge pools of hepatitis C virus genotypes 1-6 prototype strains: replication fitness and pathogenicity in chimpanzees and human liver-chimeric mouse models.Vaccine-induced HIV seropositivity: a problem on the rise.Influenza symptoms and their impact on elderly adults: randomised trial of AS03-adjuvanted or non-adjuvanted inactivated trivalent seasonal influenza vaccinesEvaluation of the safety and immunogenicity of two antigen concentrations of the Mtb72F/AS02(A) candidate tuberculosis vaccine in purified protein derivative-negative adults.
P50
Q21144344-DBA7F1AE-DA5D-4A15-ADE8-A828F4075F62Q24292983-4CE6C460-B9B0-4097-9505-E1C0F7CECD51Q24628167-2625B562-598C-40C4-B56D-663E14762E8AQ24672232-47FBAC35-0BA1-4CC5-88A6-DA82AAECA5A9Q26700078-88E0799F-F241-4ED7-9137-CE1728CC28B9Q26864485-10670F3E-A7A1-4A14-8D5D-762B342B55F1Q27469977-12E30E6A-321F-4998-ABA1-DB1272B1BD14Q27473436-03EA9E54-32F6-404F-BA7A-85F1AB6638C1Q27485033-4AE782EB-3E0A-4E81-941B-BBE5158D0F84Q27487337-C6BA2ABB-28B7-4E74-B099-A571441EE77CQ27488616-35C28C6E-A9D5-47D4-AEC8-C8E86A2FAEE9Q27666224-8534553A-C4C7-4C97-8D91-FBD6AF302612Q29544293-8AF9174B-B815-42CD-856E-21AED510F226Q30363500-61BDFEE9-F861-4CA1-B3B2-9B6863F6A61AQ30364160-A876F0DF-43FE-4867-8E03-73C5483B3A26Q30369095-0FAF665B-66BA-406E-A3F8-F358B53312F5Q30370214-D0F887EC-D68E-40BD-BA34-D66D064DD395Q30371111-AD6F18A1-A3C1-46FC-B38D-47C6025263A2Q30375975-062AFA93-18FD-4A85-90D5-31FCFBC0251CQ30378421-7A59ABF0-92C0-4A05-8505-35C91616B7ADQ30381713-7C77C9EE-B061-4E8F-BDF0-8D87B495B3EEQ30394896-B7A85978-EB84-4FF7-9152-D637323DDD94Q30397617-02DC1436-879F-46D8-AE65-63A86A5B5182Q30401398-764F76DE-7361-468E-BF67-7C80CF397706Q30414633-86DC5AB7-5B44-45FD-A521-01C34BC8FEAEQ30417211-4D7A9728-CB29-4692-847E-8BE971211D88Q33393294-D74CE153-966B-4282-899D-E557ABD1B9B7Q33578064-2DFE4CAF-7268-4AC5-A82A-B6F59B39D125Q33602744-12CCB494-8BB6-48B5-8072-098F18539933Q33684340-E1F22832-90BA-4003-9A3B-A0AC7AA3E1B4Q33724413-0C840A09-F0A1-4AA3-BA15-79A36B416434Q33960093-46A29F3A-E7F5-4B9C-8B2E-A6D931EC629BQ34047556-EF856DA4-D79A-4493-A45E-61DFBA53B4E3Q34062532-C48DABDA-1169-4CBA-8024-CE526E682380Q34096483-B99425FC-4938-4CEC-8AB0-2843670D7C86Q34131456-ED3F176E-A7EC-43A0-85DD-077F5A844F5DQ34140014-1D317DAA-DED3-44B7-B256-B40DF90F86D9Q34163124-B3173F73-CF37-487C-A92D-E9CC20627920Q34274845-3A024CD4-816C-4407-BA52-4B3496932EACQ34289930-C8631217-B6CE-427D-8644-841A65137158
P50
description
onderzoeker
@nl
name
Geert Leroux-Roels
@ast
Geert Leroux-Roels
@en
Geert Leroux-Roels
@es
Geert Leroux-Roels
@nl
Geert Leroux-Roels
@sl
type
label
Geert Leroux-Roels
@ast
Geert Leroux-Roels
@en
Geert Leroux-Roels
@es
Geert Leroux-Roels
@nl
Geert Leroux-Roels
@sl
prefLabel
Geert Leroux-Roels
@ast
Geert Leroux-Roels
@en
Geert Leroux-Roels
@es
Geert Leroux-Roels
@nl
Geert Leroux-Roels
@sl
P106
P21
P31
P569
2000-01-01T00:00:00Z